On June 19, Photogen declared it had acquired the ultrasound contrast media assets of Alliance Pharmaceutical. The next day the company announced it had filed a complaint against Amersham Health and related Amersham entities to enforce its newly acquired
On June 19, Photogen declared it had acquired the ultrasound contrast media assets of Alliance Pharmaceutical. The next day the company announced it had filed a complaint against Amersham Health and related Amersham entities to enforce its newly acquired patent portfolio. The patents relate to Photogen's FDA-approved Imagent (perflexane lipid microspheres). The ultrasound contrast agent is used in patients with suboptimal echocardiograms to opacify the left ventricle. Imagent improves visualization of the ventricle and better delineates the endocardial borders of the heart. Photogen's complaint alleges that Amersham, principally through its Optison product, has infringed seven patents owned by Photogen. In the complaint filed in U.S. District Court in New Jersey, the company seeks damages and an injunction against Amersham, as well as a declaration by Amersham that the claims of 14 Amersham patents are invalid and are not infringed by Imagent, as alleged by Amersham in a separate suit.
Imagent will be marketed through the Imcor Pharmaceutical division of Photogen. Imcor featured the product at the meeting of the American Society of Echocardiography held in Las Vegas June 11 to 14. The ASE meeting served as a coming out for Photogen's newly acquired product. The deal, which included all manufacturing and marketing rights to Imagent, was announced in December (SCAN 12/25/02). It closed in late June.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.